ARV/ART

New HIV infections are rising in around 50 countries, AIDS-related deaths are not falling fast enough and flat resources are threatening success. Half of all new HIV infections are among key populations and their partners, who are still not getting the services they need

The global AIDS response is at a precarious point—partial success in saving lives and stopping new HIV infections is giving way to complacency. At the halfway point to the 2020 targets, the pace of progress is not matching the global ambition.

Information from community-based health programs is important for understanding what HIV programs are doing to test, treat, and retain in care people who are living with HIV.

Community-based Indicators for HIV Programs: Presentation of a collection

Lopinavir/ritonavir (LPV/r) pellets are a new formulation of a pediatric HIV medicine. The LPV/r Pellet Toolkit provides information on how to implement rollout of LPV/r pellets into the national health care system in the Rollout Planning and Management section.

INTRODUCTION:

Background

INTRODUCTION:

Evidence regarding potential adverse neuropsychiatric effects of efavirenz is conflicting, and data from sub-Saharan Africa, where 70% of persons living with HIV (PLHIV) reside and efavirenz is used as first-line therapy, are limited. The objective of this study was to estimate associations betwe

Treatment with the antiretroviral drug efavirenz did not increase the risk of depressive symptoms or suicidal thoughts in adults living with HIV in Uganda when compared to nevirapine-based treatment, a prospective cohort study published in Annals of Internal Medicine reports.